Description
Aldosterone antagonism and enhanced Clearance for Health Improvement EValuation in End-stage renal disease (ACHIEVE) Trial
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02016-07-01$2,652,816
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2016-07-01(start date) | $2,652,816 | — | Aldosterone antagonism and enhanced Clearance for Health Improvement EValuation in End-stage renal disease (AC… |
Related records · 4
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2024-2025-Q1-00691 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $520,200 | FY2025 |
| 236-2022-2023-Q3-00633 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $1,208,700 | FY2023 |
| 236-2015-2016-Q2-00119 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $100,000 | FY2016 |
| 236-2015-2016-Q2-00283 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $339,916 | FY2016 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2016-2017-Q2-00128 · retrieved 2026-11-14.